-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Upgrades Biogen to Buy, Raises Price Target to $235

Benzinga·07/13/2026 10:16:05
语音播报
Truist Securities analyst Srikripa Devarakonda upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and raises the price target from $190 to $235.